Last update 23 Jan 2025

Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lobeglitazone/D745/D150
Target
PPARγ x PRKAB1 x SGLT2
Mechanism
PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication
Diabetes Mellitus, Type 2
Inactive Indication-
Originator Organization
Chong Kun Dang Pharmaceutical Corp.Chong Kun Dang Pharmaceutical Corp.
Active Organization
Chong Kun Dang Pharmaceutical Corp.Chong Kun Dang Pharmaceutical Corp.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

7
Clinical Trials associated with Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride
NCT06695598
/ RecruitingPhase 1
An Open Label, Randomized, Single Dose, Crossover, Phase I Study to Evaluate the Effects of Food on Pharmacokinetics and the Safety of CKD-383 in Healthy Adult Volunteers
NCT06695572
/ RecruitingPhase 1
An Open Label, Randomized, Single Dose, Crossover, Phase I Study to Evaluate the Effects of Food on Pharmacokinetics and the Safety of CKD-383 in Healthy Adult Volunteers
NCT06492655
/ Not yet recruitingPhase 1
A Randomized, Open-label, Single Dose, Crossover, Phase 1 Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-383 in Healthy Volunteers
100 Clinical Results associated with Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride
Login to view more data
100 Translational Medicine associated with Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride
Login to view more data
100 Patents (Medical) associated with Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride
Login to view more data
100 Deals associated with Lobeglitazone Sulfate/Empagliflozin/Metformin Hydrochloride
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 1
KR
Chong Kun Dang Pharmaceutical Corp.Chong Kun Dang Pharmaceutical Corp.
26 May 2023
Diabetes MellitusPreclinical
KR
Chong Kun Dang Pharmaceutical Corp.Chong Kun Dang Pharmaceutical Corp.
16 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free